IndustryCompany release

Beam Therapeutics flags possible risto-cel BLA by year-end as BEAM-302 pivotal dosing nears completion

🇺🇸 Beam Therapeutics Inc. (BEAM) · Tue 03 Nov 2026

The gene-editing company's third-quarter update points to a potential US filing in sickle cell disease and completed BEAM-302 pivotal dosing in H1 2027.

Beam Therapeutics reported third-quarter 2026 results on 3 November, setting out several regulatory and clinical milestones. The company said it could submit a US Biologics License Application (BLA) for risto-cel in sickle cell disease as early as the end of 2026.

In alpha-1 antitrypsin deficiency, Beam expects to complete dosing of the pivotal cohort for BEAM-302 in the first half of 2027.

The update also covered earlier-stage programmes. Beam reported initial data for BEAM-301 in glycogen storage disease type Ia (GSDIa) and said it plans to begin dosing in the BEAM-304 programme in phenylketonuria (PKU) in early 2027.

On financials, the company posted a net loss of $134.4 million for the quarter and reported about $1.0 billion in cash. Beam said this funds operations into mid-2029. The summary provided does not include further detail on the BEAM-301 data or on the content of any planned BLA.

What it means for your team

  • A risto-cel BLA could reach the US FDA as early as year-end 2026, though Beam framed the timing as a possibility rather than a firm commitment.
  • Completion of BEAM-302 pivotal dosing in H1 2027 marks a key step toward later regulatory planning for alpha-1 antitrypsin deficiency.
  • Teams tracking gene-editing therapies should note the expanding pipeline, with BEAM-301 in GSDIa and BEAM-304 in PKU, which may raise future long-term follow-up and safety monitoring questions.
  • Cash of about $1.0 billion and a runway into mid-2029 suggest Beam can fund its programmes through the stated milestones without near-term financing.

Company's press release (SEC filing): Beam Therapeutics Inc. ↗

Article written by VigiEye from the official source (Beam Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →